PVLA vs. NUVB, PRTA, BCAX, GHRS, DNTH, VERV, ORIC, KURA, QURE, and CAPR
Should you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include Nuvation Bio (NUVB), Prothena (PRTA), Bicara Therapeutics (BCAX), GH Research (GHRS), Dianthus Therapeutics (DNTH), Verve Therapeutics (VERV), ORIC Pharmaceuticals (ORIC), Kura Oncology (KURA), uniQure (QURE), and Capricor Therapeutics (CAPR). These companies are all part of the "pharmaceutical preparations" industry.
Palvella Therapeutics vs.
Nuvation Bio (NYSE:NUVB) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking.
61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 5.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 6.4% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Nuvation Bio has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
Nuvation Bio received 42 more outperform votes than Palvella Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Palvella Therapeutics an outperform vote while only 80.00% of users gave Nuvation Bio an outperform vote.
Palvella Therapeutics has higher revenue and earnings than Nuvation Bio. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.
Nuvation Bio currently has a consensus price target of $8.20, suggesting a potential upside of 271.88%. Palvella Therapeutics has a consensus price target of $40.33, suggesting a potential upside of 109.85%. Given Nuvation Bio's higher possible upside, equities research analysts plainly believe Nuvation Bio is more favorable than Palvella Therapeutics.
Nuvation Bio's return on equity of -21.89% beat Palvella Therapeutics' return on equity.
In the previous week, Palvella Therapeutics had 4 more articles in the media than Nuvation Bio. MarketBeat recorded 6 mentions for Palvella Therapeutics and 2 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.97 beat Palvella Therapeutics' score of 0.32 indicating that Nuvation Bio is being referred to more favorably in the media.
Summary
Nuvation Bio beats Palvella Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Palvella Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palvella Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PVLA) was last updated on 2/23/2025 by MarketBeat.com Staff
